Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Tarvacin & #153 Equivalent (3G4) Plus Radiation Reduces Lung Tumor Growth By Over 95%

By Pharmaceutical Processing | April 20, 2005

TUSTIN, Calif., April 18 — Peregrine Pharmaceuticals Inc. reported that data will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Anaheim, California related to Tarvacin&#153, its lead Anti-Phospholipid Therapy agent. The data to be presented shows that 3G4, the mouse version of Tarvacin&#153, is active against a number of solid tumors including lung, prostate, pancreatic, fibrosarcoma and breast cancers given as a single agent or in combination with either chemotherapy or radiation therapy. In a pre-clinical lung cancer model, the combination of 3G4 plus radiation therapy inhibited tumor growth by over 95% and 3G4 alone decreased tumor growth by 62%. In pancreatic pre-clinical tumor therapy experiments, 3G4 plus the chemotherapeutic agent gemcitabine decreased primary tumor growth by 60% and essentially stopped metastasis to liver and lymph nodes.

“These pre-clinical data in a variety of tumor types are extremely valuable since our phase I clinical trial for Tarvacin&#153 allows inclusion of patients with any solid tumor type.” said Steven King, president and CEO of Peregrine Pharmaceuticals. “In particular, pre-clinical results investigating different combinations of Tarvacin&#153 with standard cancer therapies should prove especially helpful in guiding the clinical program.” Peregrine expects to begin patient enrollment in the Tarvacin(TM) phase I clinical trial within the next 30 days.”

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE